<DOC>
	<DOC>NCT01786668</DOC>
	<brief_summary>This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.</brief_summary>
	<brief_title>Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Documented diagnosis of Ankylosing Spondylitis Has active disease despite concurrent nonsteroidal antiinflammatory drugs (NSAIDs) treatment or is intolerant to NSAIDs Pregnant or lactating females Currently receiving or previous use of a Tumor Necrosis Factor (TNF) inhibitor or any biological agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Spondylitis</keyword>
	<keyword>Ankylosing</keyword>
	<keyword>Spondyloarthritis</keyword>
	<keyword>Spondyloarthropathy</keyword>
	<keyword>Oral preparation</keyword>
</DOC>